Finally, Porcu et al. demonstrated that BRCA-1 patients exhibited significantly lower levels of anti-Müllerian hormone (AMH) compared to BC patients without BRCA mutation and control women, concluding that BRCA-1 patients could have a higher risk of developing premature ovarian insufficiency (POI), together with a lower ovarian reserve [25]. The gene discussed is AMH; the disease is breast cancer.